Bamberger Federführer. Die besten Texte aus drei Jahren Literaturwettbewerb an der Universität Bamberg (2009-2011)

Im Kreise des Redaktions-Teams der studentischen Hochschulgruppe Feki.de entstand im November 2008 die Idee, einen Literaturwettbewerb an der Universität Bamberg zu etablieren. Das Projekt sollte es Studierenden aller Fachrichtungen ermöglichen, literarisch tätig zu werden und sich mit ihren Texten dem Urteil einer Jury bzw. der Leser zu stellen. Insgesamt drei Mal wurde der Wettbewerb durchgeführt: 2009 wurde die beste Kurzgeschichte zum Thema „Um 20 Uhr am Gabelmoo“ gesucht, im Jahr darauf lautete das Thema schlicht „fertig. Der letzte Wettbewerb stand schließlich unter dem Motto „Heimat“. Die Auswahl der Siegertexte übernahm eine Jury, bestehend aus Vertretern verschiedener Hochschulgruppen – Feki.de, Rezensöhnchen und Ottfried –, Prof. Dr. Andrea Bartl, Inhaberin der Professur für Neuere deutsche Literaturwissenschaft, dem Autor und Kritiker Rolf Bernhard Essig sowie wechselnd den Autoren Nora Gomringer, Kurt Kreiler und Nefvel Cumart. Daneben konnten die Feki.de-Leser über den jeweiligen Publikumspreisträger abstimmen. Neben den Studierenden der Universität Bamberg waren ab dem zweiten Jahr auch Teilnehmer der Schreibwerkstatt der JVA Ebrach eingeladen, ihre Texte einzu­senden. Im Vergleich mit den studentischen Texten boten die Beiträge der Gefangenen einen interessanten Perspektivwechsel für alle Teil­nehmer und Leser. Insgesamt 24 Kurzgeschichten aus den Jahren 2009 bis 2011 haben wir in diesem Band zusammengestellt. Neben den jeweiligen Siegertexten finden sich in der Anthologie auch die Beiträge der JVA-Bewohner zum Thema „fertig“, sowie ausgewählte Texte Studierender, die die Podestplätze nur knapp verfehlten

Volume CXIV, Number 4, November 7, 1996

Objective: Turner syndrome (TS) is a chromosomal disorder caused by complete or partial X chromosome monosomy that manifests various clinical features depending on the karyotype and on the genetic background of affected girls. This study aimed to systematically investigate the key clinical features of TS in relationship to karyotype in a large pediatric Turkish patient population.Methods: Our retrospective study included 842 karyotype-proven TS patients aged 0-18 years who were evaluated in 35 different centers in Turkey in the years 2013-2014.Results: The most common karyotype was 45,X (50.7%), followed by 45,X/46,XX (10.8%), 46,X,i(Xq) (10.1%) and 45,X/46,X,i(Xq) (9.5%). Mean age at diagnosis was 10.2±4.4 years. The most common presenting complaints were short stature and delayed puberty. Among patients diagnosed before age one year, the ratio of karyotype 45,X was significantly higher than that of other karyotype groups. Cardiac defects (bicuspid aortic valve, coarctation of the aorta and aortic stenosis) were the most common congenital anomalies, occurring in 25% of the TS cases. This was followed by urinary system anomalies (horseshoe kidney, double collector duct system and renal rotation) detected in 16.3%. Hashimoto's thyroiditis was found in 11.1% of patients, gastrointestinal abnormalities in 8.9%, ear nose and throat problems in 22.6%, dermatologic problems in 21.8% and osteoporosis in 15.3%. Learning difficulties and/or psychosocial problems were encountered in 39.1%. Insulin resistance and impaired fasting glucose were detected in 3.4% and 2.2%, respectively. Dyslipidemia prevalence was 11.4%.Conclusion: This comprehensive study systematically evaluated the largest group of karyotype-proven TS girls to date. The karyotype distribution, congenital anomaly and comorbidity profile closely parallel that from other countries and support the need for close medical surveillance of these complex patients throughout their lifespa

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Herausforderung Bologna: Reorganisation und IT-Unterstützung als Erfolgsfaktoren einer praktischen Umsetzung

Neben der Digitalisierung der Wissenschaft wird durch die Umstellung der Studiengänge auf Bachelor- und Masterabschlüsse ein hoher Modernisierungsdruck auf Universitäten ausgeübt. Dieser Beitrag beschreibt die Faktoren einer erfolgreichen Einführung gestufter Studiengänge an einer großen Fakultät für Wirtschaftswissenschaften. Dabei wurden die Interessen aller Beteiligten gebündelt und Mehrbelastungen durch eine gezielte Prozess-Reorganisation und IT-Unterstützung entgegengewirkt. (DIPF/Orig.

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone

Abstract Background Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of immune checkpoint inhibition. Since bone metastases are not measurable lesions per standard response criteria, the efficacy of immune checkpoint inhibition in the bones is also not well described. Case presentation We describe a patient with widespread melanoma metastases involving the bone marrow causing myelophthisis and pancytopenia who responded to immune checkpoint inhibition with the anti-programmed cell death-1 (PD-1) inhibitor pembrolizumab. Conclusions This is the first report to our knowledge of disease response to immune checkpoint inhibition in a patient with myelophthisis. Clinical trials have recently emerged describing the efficacy of PD-1 inhibition for disorders regularly involving the bone marrow, such as hematologic malignancies, suggesting the importance of better understanding the bone marrow as an immunologically active compartment. Clinicians should be aware that immune checkpoint inhibition alone may be effective in treating malignancy involving the bone marrow, even in cases of extensive involvement resulting in pancytopenia due to myelophthisis from a solid tumor as our case suggests

Leiomyoma of Oral Cavity: Case Report and Literature Review

Leiomyoma is a benign smooth muscle tumor that can be observed at any region but is mostly observed in the female genital tract. Although leiomyomas are uncommon in the oral cavity, they are usually observed on the lips, tongue, and palate. Here we present a case report of leiomyoma in a female patient along with the literature review. A 35-year-old Turkish female presented with a 1-year history of a well-delineated, asymptomatic, and soft mass on the vestibule alveolar mucosa of the right mandibular molar region. Under local anesthesia, excisional biopsy was performed and the specimen was sent for histopathological examination. The histopathological diagnosis was leiomyoma. Based on clinical appearance, it is very challenging to distinguish a leiomyoma from other mesenchymal-origin tumors. Histological analysis determined the final diagnosis of oral leiomyoma, and surgery was performed because it was the only option for the treatment of these lesions